In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
08 09 2021
Historique:
received: 05 05 2020
accepted: 18 08 2021
entrez: 9 9 2021
pubmed: 10 9 2021
medline: 15 12 2021
Statut: epublish

Résumé

In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the creation of a class of monovalent protein therapeutics that includes fusion proteins and bispecific targeting molecules. Here we report a structure-guided approach to engineer monomeric Fc molecules to adapt multiple versions of half-life extension modifications. Co-crystal structures of these monomeric Fc variants with Fc neonatal receptor (FcRn) shed light into the binding interactions that could serve as a guide for engineering the half-life of antibody Fc fragments. These engineered monomeric Fc molecules also enabled the generation of a novel monovalent bispecific molecular design, which translated the FcRn binding enhancement to improvement of in vivo serum half-life.

Identifiants

pubmed: 34497355
doi: 10.1038/s42003-021-02565-5
pii: 10.1038/s42003-021-02565-5
pmc: PMC8426389
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Immunoglobulin Fc Fragments 0
Receptors, Fc 0
Fc receptor, neonatal TW3XAW0RCY

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1048

Subventions

Organisme : NIGMS NIH HHS
ID : P41 GM103393
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):22-5
pubmed: 20057045
J Pharm Sci. 2013 Dec;102(12):4315-29
pubmed: 24136070
J Biol Chem. 2015 Feb 13;290(7):4282-90
pubmed: 25538249
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
Biomaterials. 2017 Feb;117:24-31
pubmed: 27923197
Xenobiotica. 2014 Dec;44(12):1127-34
pubmed: 25030041
J Am Chem Soc. 2011 Jul 6;133(26):10302-11
pubmed: 21627172
Biochemistry. 1999 Sep 28;38(39):12639-47
pubmed: 10504233
Neuron. 2014 Jan 8;81(1):49-60
pubmed: 24411731
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Nat Commun. 2018 Feb 12;9(1):621
pubmed: 29434196
MAbs. 2015;7(5):922-30
pubmed: 26179052
J Pharm Sci. 2008 Apr;97(4):1414-26
pubmed: 17721938
Biophys J. 2000 Mar;78(3):1606-19
pubmed: 10692345
Mol Cell. 2001 Apr;7(4):867-77
pubmed: 11336709
Crit Rev Biotechnol. 2015 Jun;35(2):235-54
pubmed: 24156398
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
Curr Protoc Immunol. 2008 May;Chapter 18:Unit 18.15
pubmed: 18491296
Acta Crystallogr D Biol Crystallogr. 2015 Nov;71(Pt 11):2354-61
pubmed: 26527150
Clin Cancer Res. 2016 Jul 15;22(14):3440-50
pubmed: 26847056
Nat Rev Immunol. 2007 Sep;7(9):715-25
pubmed: 17703228
Oncoimmunology. 2017 Sep 27;7(1):e1377874
pubmed: 29296540
MAbs. 2019 Oct;11(7):1276-1288
pubmed: 31216930
MAbs. 2015;7(2):377-89
pubmed: 25621507
Protein Cell. 2018 Jan;9(1):15-32
pubmed: 28421387
MAbs. 2019 Feb/Mar;11(2):219-238
pubmed: 30516432
MAbs. 2016 Aug-Sep;8(6):1010-20
pubmed: 27285945
Drug Discov Today. 2005 Sep 15;10(18):1237-44
pubmed: 16213416
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9
pubmed: 2025413
Front Immunol. 2020 Jun 30;11:1301
pubmed: 32695107
Nat Biotechnol. 2014 Jan;32(1):40-51
pubmed: 24406927
J Biol Chem. 2013 Jun 7;288(23):16529-16537
pubmed: 23615911
Pharmacol Ther. 2019 Sep;201:103-119
pubmed: 31028837
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
J Pharm Sci. 2004 Sep;93(9):2184-204
pubmed: 15295780
MAbs. 2013 May-Jun;5(3):406-17
pubmed: 23567207
BioDrugs. 2015 Aug;29(4):215-39
pubmed: 26177629
Methods Mol Biol. 2016;1441:333-46
pubmed: 27177679
Nat Biotechnol. 1997 Jul;15(7):637-40
pubmed: 9219265
Annu Rev Immunol. 1993;11:331-60
pubmed: 8476565
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96
pubmed: 23882082
Proc Natl Acad Sci U S A. 1969 May;63(1):78-85
pubmed: 5257969
PLoS One. 2016 Aug 01;11(8):e0160345
pubmed: 27479095
J Biol Chem. 2014 Mar 14;289(11):7812-24
pubmed: 24469444
Proteins. 2013 Apr;81(4):592-606
pubmed: 23180599
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
J Immunol. 2002 Nov 1;169(9):5171-80
pubmed: 12391234

Auteurs

Lu Shan (L)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA. shan@dnli.com.
Denali Therapeutics, South San Francisco, CA, USA. shan@dnli.com.

Nydia Van Dyk (NV)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

Nantaporn Haskins (N)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

Kimberly M Cook (KM)

Early Oncology, R&D, AstraZeneca, Gaithersburg, MD, USA.

Kim L Rosenthal (KL)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

Ronit Mazor (R)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Division of Cellular and Gene Therapies, FDA Center for Biologics Evaluation and Research, Silver Spring, MD, USA.

Sonia Dragulin-Otto (S)

Dosage Form Design and Development, R&D, AstraZeneca, Gaithersburg, MD, USA.

Yu Jiang (Y)

Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Gaithersburg, MD, USA.

Herren Wu (H)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

William F Dall'Acqua (WF)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

Martin J Borrok (MJ)

Janssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.

Melissa M Damschroder (MM)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

Vaheh Oganesyan (V)

Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA. vaheh.oganesyan@AstraZeneca.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH